TLDRIonQ and QC Ware test hybrid quantum chemistry for faster drug discovery researchIonQ Forte supports eight-qubit chemistry calculations through Amazon Braket cloudQC Ware reports interaction-energy results that meet chemical accuracy standardsPromethium links GPU processing with IonQ Forte for advanced molecular modellingIonQ partnership expands trapped-ion quantum applications in pharmaceutical researchIonQ shares fell 4.02% to $37.73 as QC Ware reported a hybrid chemistry test using IonQ Forte. The project combined GPU processing with trapped-ion quantum computing through Amazon Braket. The test targeted quantum-assisted calculations for early drug discovery work.IonQ, Inc., IONQIonQ Stock Slips as Partnership Expands Quantum WorkIonQ stock extended its decline from about $39.30 and traded at $37.73 during the session. Meanwhile, QC Ware used IonQ Forte to test a workflow for complex molecular interactions. The demonstration focused on research applications rather than broad commercial deployment or clinical use.QC Ware selected the heme active site of cytochrome P450nor for the test. The enzyme belongs to cytochrome P450, and this family drives much of human drug metabolism. Therefore, the model provided a relevant setting for studying drug binding and metabolic behavior.Better interaction-energy calculations could improve candidate ranking during pharmaceutical research, according to the companies. Earlier ranking can help research teams focus resources on compounds with stronger predicted characteristics. It can also support earlier metabolic risk checks before compounds enter costly development stages.IonQ Forte Handles Eight-Qubit Chemistry CalculationPromethium prepared a 115-atom model containing more than 1,000 molecular orbitals. The platform isolated four strongly correlated orbitals and mapped the active space onto eight qubits. IonQ Forte measured those qubits before Promethium completed final interaction-energy calculations using classical resources.The workflow calculated electrostatic interaction energy within 0.5 kilocalories per mole of classical benchmarks. That result remained inside the one-kilocalorie-per-mole level commonly linked with chemical accuracy. The companies also reported more than twice the accuracy of the standard classical mean-field method.IonQ Forte uses trapped ions and provides all-to-all connectivity between qubits. That connectivity enabled complex two-qubit operations without routing steps required by limited-connectivity designs. As a result, the test applied QC Ware’s workflow to another quantum architecture without changing its core approach.AWS Braket Supports Cloud-Based Quantum Chemistry TestAmazon Web Services supported the demonstration with cloud computing credits through Amazon Braket. The setup connected QC Ware’s GPU-native Promethium platform with IonQ Forte through cloud infrastructure. This structure showed how classical computing can work with remote quantum hardware inside one workflow.QC Ware developed Promethium to run chemistry calculations across larger molecular systems and compound sets. QC Ware reports speed gains up to 20 times over conventional CPU-based DFT platforms for selected workloads. Those speed gains target drug discovery, catalysis, materials science, and other chemistry-intensive applications.For IonQ, the project adds another applied example for its trapped-ion quantum technology. The demonstration expands IonQ’s chemistry presence, and accurate molecular calculations remain resource intensive. However, the test measured technical performance and did not establish clinical effectiveness or broader commercial results. The post IonQ, Inc. (IONQ) Stock: QC Ware Partnership Targets Quantum Drug Discovery appeared first on Blockonomi.